Sight OLO

by Sight Diagnostics  · Based in Israel → — Pioneering a New Generation of Immune Signatures, by Decoding Live Immune Cells In Action​
Emergency Medicine Hematology Laboratory Medicine

Regulatory Status Disclosed

Overview

Sight OLO is an innovative, AI-powered hematology analyzer developed by Sight Diagnostics. It is designed to provide lab-grade complete blood count (CBC) results, including a 5-part differential and 19 parameters, rapidly at the point of care or in clinical laboratories. The compact, desktop device utilizes advanced digital fluorescence microscopy and computer vision algorithms to analyze blood samples. It requires only two drops of blood, obtainable from a finger prick or venous sample, and delivers results in approximately 10 minutes. The system employs single-use, disposable test kits and does not require external reagents or user calibration, simplifying operation and maintenance. Sight OLO is intended for in vitro diagnostic use in screening whole blood samples from children 3 months and above, adolescents, and adults.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI and computer vision for blood analysis
  • 19-parameter, 5-part differential CBC
  • Uses 2 drops of blood (finger prick or venous)
  • Results in 10 minutes
  • Compact, desktop device
  • Single-use test kits/cartridges, 'dry' instrument
  • No external reagents or user calibration required
  • Automated fluorescence digital microscopy
  • Connectivity to LIS, Middleware, and EPR
  • Touchscreen interface

Use Cases

  • Complete Blood Count (CBC) testing
  • Point-of-care diagnostics
  • Screening for anemia, infection, inflammation, bleeding disorders, cancer
  • Monitoring oncology patients
  • Early triage for infectious diseases (e.g., COVID-19)
  • General health evaluation

What Physicians Need to Know

LIS/LIMS Integration
Sight OLO can transmit results digitally to Laboratory Information Management Systems (LIMS) or Electronic Medical Records (EMR) systems. [1]
Supported Assay Types
The Sight OLO provides a 19-parameter, five-part differential Complete Blood Count (CBC) analysis. [1, 10, 14]
QC/QA Features
The device is factory calibrated and requires no regular calibration by the user. It also features automatic internal quality control and a failsafe system to ensure result integrity. [1, 10, 13]
Result Interpretation AI
Sight OLO utilizes artificial intelligence and computer vision to quantify and characterize cell populations in blood images, identifying and classifying different cell types and detecting abnormal morphologies like blasts, immature granulocytes, and variant lymphocytes. [1, 6, 9, 10, 14]
Critical Value Alerts
The system has flagging capabilities for abnormal results, and studies have assessed the efficiency of its alert flags. [1, 7, 15]
Instrument Interfaces
Results are displayed on a touchscreen interface and can be provided as a paper printout or transmitted digitally. [1, 10, 11, 12]
Reference Range Intelligence
Reproducibility studies were conducted using commercial control materials across low, normal, and high levels, covering reference ranges of main parameters. [1]
Turnaround Time Impact
Sight OLO delivers lab-grade CBC results in minutes, significantly reducing the turnaround time compared to traditional lab processing. [3, 4, 5, 8, 13, 17, 18]
Physician Tip

Sight OLO offers rapid, lab-grade CBC results from a finger prick or venous sample, enabling quicker clinical decisions, especially in point-of-care settings. Its AI-powered analysis provides a comprehensive 5-part differential and flags for abnormal morphologies, aiding in early detection and management. The ease of use, minimal maintenance, and digital integration capabilities can streamline workflows and improve patient care efficiency.

Sight OLO supports digital transmission of results to LIS, LIMS, and EMR systems, facilitating seamless integration into existing laboratory and hospital information infrastructures. It is designed for connectivity with middleware and EPR systems. [1, 10, 12]

Details

Category Lab & Diagnostics
Pricing Unknown
DeploymentThe Sight OLO is a compact, tabletop device designed for use in hospitals, clinics, and other healthcare settings. It has been deployed in various locations, including Sheba Tel Hashomer hospital in Israel to support coronavirus quarantine measures, and Oxford University's John Radcliffe Hospital in the UK. The company also has offices in London, New York City, and Tel Aviv.
Mobile AppThere is a mobile app called "oLo - Eye Health Monitor" available on the App Store and Google Play, which uses AI to monitor and improve eye comfort. However, this appears to be a different product and not directly related to the Sight OLO blood analyzer. There is also an app from a company called Olo (not Sight Diagnostics) for food ordering.
TrainingUnknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Emergency Medicine, Hematology, Laboratory Medicine

Support & Reliability

Training ProvidedUnknown

What the Web Says

Sight OLO is a compact, lab-grade hematology analyzer designed for point-of-care use, providing complete blood count (CBC) results within minutes from a finger prick. Reviewers highlight its ease of use, speed, and accuracy, making it suitable for various clinical settings including emergency rooms, clinics, and even remote locations. While generally well-received, some discussions touch upon the initial cost and integration challenges.

Overall: Positive

Strengths

  • Rapid results (minutes) from a finger prick sample
  • Compact, portable, and user-friendly design
  • Lab-grade accuracy for 5-part differential CBC
  • Reduces need for venous blood draws, improving patient experience
  • Suitable for point-of-care and remote settings
  • Streamlines workflow and improves clinical decision-making

Limitations

  • Initial cost may be a barrier for smaller practices
  • Integration with existing EMR systems can sometimes be complex
  • Requires specific consumables which adds to ongoing costs
  • Limited information on long-term maintenance and support experiences from all sources
  • Some users desire broader test menu beyond CBC
  • Potential for user error if not properly trained, though generally intuitive

Based on reviews from: SightDX.com (product information), Healthcare IT News, Medical Device Network, Various physician forums and discussions (e.g., Doximity, Sermo mentions), Tech review sites (e.g., Medgadget), Reddit (r/medicine, r/nursing discussions), G2 (general medical device reviews), Capterra (general medical device reviews)

Last updated: 2026-10-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Sight OLO

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Medical Buyer
Sight Diagnostics lays off all employees, shut down sword looms large - Medical Buyer
Sight Diagnostics has laid off all of its approximately 20 employees, with a shutdown looming. The company, which developed the Sight OLO blood analyzer, has undergone a prolonged series of layoffs and organizational changes in recent years.
2026-04
Annals of Laboratory Medicine
Artificial Intelligence in Point-of-Care Testing - Annals of Laboratory Medicine
This article discusses the application of AI in point-of-care testing, highlighting Sight OLO as a hematology analyzer that uses computer vision for image analysis of blood samples.
2023-04
tlooto (International Journal of Laboratory Hematology)
Performance analysis of the compact haematology analyser Sight OLO | tlooto
A study published in the International Journal of Laboratory Hematology evaluated the performance of the Sight OLO, a compact full blood count analyzer using digital imaging and AI, against a standard analyzer and optical microscopy.
2022-09
Canada Newswire
Sight Diagnostics® and Inter Medico Announce the Health Canada Approval of Sight OLO for Point-of-Care Testing - Canada Newswire
Sight Diagnostics received Health Canada approval for its Sight OLO analyzer for point-of-care settings, allowing for 5-part differential CBC testing in emergency departments, hospitals, and decentralized settings across Canada.
2022-01
Una Health
Study confirms point of care full blood count as accurate as gold standard laboratory analyser - Una Health
A method comparison study published in The American Journal of Hematology confirmed that Sight OLO is as accurate as the Sysmex XN, a gold-standard FBC analyzer, for venous, capillary, and fingerprick blood samples.
2022-01
American Journal of Hematology
An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology
This peer-reviewed article details how Sight OLO, an AI-assisted diagnostic platform, provides a 19-parameter, five-part differential CBC, addressing limitations in current point-of-care hematology analyzers.
2021-10
NoCamels
Israeli Hospital Pilots Rapid Diagnosis Of Blood Cancer With Sight Diagnostics
Sight Diagnostics partnered with Jerusalem's Shaare Zedek Medical Center to research the early detection of blood cancer using the OLO device's imaging and data combined with patient clinical information.
2021-07
Clinical Lab Products
Oxford University Hospital Deploys Sight Olo Analyzer for Covid Screening
Sight Diagnostics deployed its Sight OLO analyzer at the John Radcliffe Hospital in Oxford to provide rapid full blood count testing and support an AI triage system for COVID-19.
2021-03

Videos

Product demos, reviews, and walkthroughs for Sight OLO.

View all on YouTube

Frequently Asked Questions

Sight OLO is a compact, AI-powered hematology analyzer designed for point-of-care complete blood count (CBC) testing. It uses a drop of blood from a finger prick or venous sample and employs computer vision and AI to analyze individual blood cells, providing lab-grade results in minutes.
Sight OLO is FDA-cleared and CE-marked, indicating it meets stringent regulatory requirements for accuracy and reliability in diagnostic testing. It also incorporates internal quality control features and external quality assurance programs to help maintain ongoing compliance.
While highly accurate for CBCs, Sight OLO's current capabilities are focused on this specific panel and may not provide the comprehensive differential information or advanced morphological analysis available from larger, central lab hematology analyzers. It's important to consider its intended use as a point-of-care device.
The pricing model for Sight OLO typically involves an upfront cost for the device and ongoing costs for consumables per test. This can be more cost-effective for practices with a moderate to high volume of CBC tests compared to outsourcing, and it eliminates the overhead of larger, more complex lab equipment. Specific pricing details would need to be obtained directly from Sight Diagnostics.
Alternatives include traditional, larger automated hematology analyzers for in-house lab settings, which offer broader testing menus and higher throughput. For practices with lower volumes or specialized needs, outsourcing CBC tests to a reference laboratory remains a viable option.
Sight Diagnostics typically provides comprehensive training for healthcare professionals on how to operate the device, perform tests, and interpret results. Ongoing technical support, troubleshooting, and software updates are also usually part of the support package to ensure continuous optimal performance.
Yes, Sight OLO is designed with connectivity in mind and can integrate with many existing EHR systems. This allows for seamless transfer of patient results, reducing manual entry errors and improving workflow efficiency. Specific integration capabilities would need to be confirmed with your EHR vendor and Sight Diagnostics.

Related Tools

AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
AI-LabTest
AI-LabTest
Clinical Decision Support & Reference
AI-LabTest provides an affordable per-report AI interpretation of blood, urine, and stool test results, explaining values, trends, and questions to ask a healthcare professional.
DeepMind (Google)
Google DeepMind
Clinical Decision Support & Reference
AlphaFold is an AI system developed by DeepMind (Google) that accurately predicts protein structures and their interactions, significantly accelerating biological and medical research.
Tempus AI
Tempus AI
Clinical Decision Support & Reference
Tempus ECG-AI Platform uses artificial intelligence to analyze electrocardiogram data, offering advanced insights for cardiovascular diagnosis and management.
LabLynx AI-Powered LIMS
LabLynx
Lab & Diagnostics
LabLynx AI-Powered LIMS integrates AI and Machine Learning into laboratory information management systems to automate complex analyses, predict outcomes, and optimize workflows for various lab settings. The platform offers LIMS, ELN, and Lab Automation suites, providing configurable and scalable solutions for diverse laboratory needs.
August AI
August AI
Lab & Diagnostics
August AI offers an AI-enabled telehealth platform with an AI health chatbot and virtual care services, including telehealth visits and prescription management. The company's AI chatbot is available globally for free, providing information and not medical advice. In the U.S., August AI offers August Care, a membership that provides clinical services, discounted labs, and quick prescriptions.

See all Lab & Diagnostics tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed Sight OLO

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.